- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07489495
Un estudio clínico de Belzutifan (MK-6482) y Zanzalintinib en personas con carcinoma de células renales (CCR) (LITESPARK-034/LS-034/MK-6482-034)
Un estudio de fase 3, aleatorizado y doble ciego de belzutifan + zanzalintinib frente a belzutifan + placebo en participantes con carcinoma de células renales avanzado que han progresado durante o después de terapias con PD-1/L1 y VEGF-TKI en secuencia o en combinación (LITESPARK-034)
Researchers are looking for new ways to treat advanced renal cell carcinoma (RCC).
A standard (usual) treatment for certain people with RCC is belzutifan (a study medicine), which is a targeted therapy. Targeted therapy is a treatment that works to control how specific types of cancer cells grow and spread. Researchers want to learn if adding another targeted therapy called zanzalintinib (another study medicine) can treat more people with advanced RCC than belzutifan alone.
The goal of this study is to learn if people who receive belzutifan and zanzalintinib live longer overall and without the cancer getting worse compared to people who receive belzutifan and placebo.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Toll Free Number
- Número de teléfono: 1-888-577-8839
- Correo electrónico: Trialsites@msd.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 10117
- Reclutamiento
- Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 1312)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4930450515288
-
-
Bavaria
-
Augsburg, Bavaria, Alemania, 86156
- Reclutamiento
- Universitaetsklinikum Augsburg ( Site 1316)
-
Contacto:
- Study Coordinator
- Número de teléfono: +498214002348
-
Munich, Bavaria, Alemania, 81675
- Reclutamiento
- klinikum rechts der isar der technischen universität münchen ( Site 1315)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00498941402522
-
-
Thuringia
-
Jena, Thuringia, Alemania, 07747
- Reclutamiento
- Universitätsklinikum Jena ( Site 1313)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4936419329970
-
-
-
-
-
CABA, Argentina, C1426ANZ
- Reclutamiento
- Instituto Alexander Fleming ( Site 0252)
-
Contacto:
- Study Coordinator
- Número de teléfono: +541132218900
-
La Rioja, Argentina, X5004BAL
- Reclutamiento
- Centro Oncológico Riojano Integral ( Site 0256)
-
Contacto:
- Study Coordinator
- Número de teléfono: +543804436443X108
-
San Juan, Argentina, J5402BGA
- Reclutamiento
- COE (Centro Oncológico de Excelencia) ( Site 0259)
-
Contacto:
- Study Coordinator
- Número de teléfono: +54 2644229585
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1426AHB
- Reclutamiento
- Centro Oncologico Korben ( Site 0254)
-
Contacto:
- Study Coordinator
- Número de teléfono: +541159507952
-
Ciudad de Buenos Aires, Buenos Aires, Argentina, 1181
- Reclutamiento
- Hospital Italiano de Buenos Aires ( Site 0253)
-
Contacto:
- Study Coordinator
- Número de teléfono: +541149590200
-
Mar del Plata, Buenos Aires, Argentina, B7600FZO
- Reclutamiento
- Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250)
-
Contacto:
- Study Coordinator
- Número de teléfono: +542234963224
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, X5800ALB
- Reclutamiento
- Centro Privado de RMI Río Cuarto S.A. II ( Site 0255)
-
Contacto:
- Study Coordinator
- Número de teléfono: +543584620273
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSV
- Reclutamiento
- Sanatorio Parque ( Site 0251)
-
Contacto:
- Study Coordinator
- Número de teléfono: +5493416955611
-
Rosario, Santa Fe Province, Argentina, S2000KZE
- Reclutamiento
- Instituto de Oncología de Rosario ( Site 0257)
-
Contacto:
- Study Coordinator
- Número de teléfono: +543414484830
-
-
-
-
New South Wales
-
Macquarie University, New South Wales, Australia, 2109
- Suspendido
- Macquarie University ( Site 2700)
-
-
Queensland
-
Woolloongabba, Queensland, Australia, 4102
- Suspendido
- Princess Alexandra Hospital ( Site 2703)
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Suspendido
- Peter MacCallum Cancer Centre ( Site 2702)
-
-
Western Australia
-
Murdoch, Western Australia, Australia, 6150
- Suspendido
- Fiona Stanley Hospital ( Site 2704)
-
-
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brasil, 29055-450
- Reclutamiento
- CEDOES ( Site 0303)
-
Contacto:
- Study Coordinator
- Número de teléfono: +552721250202
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80510-130
- Reclutamiento
- Instituto do Câncer e Transplante de Curitiba ( Site 0300)
-
Contacto:
- Study Coordinator
- Número de teléfono: +55 41 99205-7755
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasil, 59062-000
- Reclutamiento
- Liga Norte Riograndense Contra o Câncer ( Site 0307)
-
Contacto:
- Study Coordinator
- Número de teléfono: +55 84 4009-5595
-
-
São Paulo
-
Ribeirão Preto, São Paulo, Brasil, 14026-610
- Reclutamiento
- Hope - Humanizacao Em Oncologia, Pesquisa E Ensino ( Site 0306)
-
Contacto:
- Study Coordinator
- Número de teléfono: +55 16 3913-8181
-
São José do Rio Preto, São Paulo, Brasil, 15090-000
- Reclutamiento
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0302)
-
Contacto:
- Study Coordinator
- Número de teléfono: +55 17 3201-5054
-
-
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H 8L6
- Reclutamiento
- The Ottawa Hospital Cancer Centre ( Site 0003)
-
Contacto:
- Study Coordinator
- Número de teléfono: 613-737-7700
-
-
Quebec
-
Québec, Quebec, Canadá, G1J 1Z4
- Reclutamiento
- Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001)
-
Contacto:
- Study Coordinator
- Número de teléfono: 418-525-4444
-
-
-
-
-
Hradec Králové, Chequia, 500 05
- Reclutamiento
- Fakultni nemocnice Hradec Kralove ( Site 0902)
-
Contacto:
- Study Coordinator
- Número de teléfono: +420727854666
-
Olomouc, Chequia, 779 00
- Reclutamiento
- Fakultni nemocnice Olomouc ( Site 0901)
-
Contacto:
- Study Coordinator
- Número de teléfono: +420588445923
-
Prague, Chequia, 150 06
- Reclutamiento
- Fakultni nemocnice v Motole ( Site 0900)
-
Contacto:
- Study Coordinator
- Número de teléfono: +420734236410
-
Prague, Chequia, 128 08
- Reclutamiento
- Fakulti poliklinika ( Site 0906)
-
Contacto:
- Study Coordinator
- Número de teléfono: +420224966405
-
-
Brno-mesto
-
Brno, Brno-mesto, Chequia, 656 53
- Reclutamiento
- Masarykuv onkologicky ustav ( Site 0903)
-
Contacto:
- Study Coordinator
- Número de teléfono: +420543132216
-
-
Ostrava Mesto
-
Ostrava, Ostrava Mesto, Chequia, 708 52
- Reclutamiento
- Fakultni nemocnice Ostrava ( Site 0904)
-
Contacto:
- Study Coordinator
- Número de teléfono: +420597374322
-
-
-
-
Coquimbo Region
-
La Serena, Coquimbo Region, Chile, 1720430
- Reclutamiento
- IC La Serena Research ( Site 0405)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56958646664
-
-
Los Lagos Region
-
Port Montt, Los Lagos Region, Chile, 5500243
- Reclutamiento
- Clínica Puerto Montt ( Site 0404)
-
Contacto:
- Study Coordinator
- Número de teléfono: +56985383586
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500921
- Reclutamiento
- Fundacion Arturo Lopez Perez ( Site 0401)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56224205098
-
Santiago, Region M. de Santiago, Chile, 8420383
- Reclutamiento
- Bradfordhill ( Site 0400)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56229490970
-
-
Valparaiso
-
Viña del Mar, Valparaiso, Chile, 2520598
- Reclutamiento
- ONCOCENTRO APYS ( Site 0403)
-
Contacto:
- Study Coordinator
- Número de teléfono: 56323320850
-
-
-
-
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center ( Site 2901)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82-2-3010-5977
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center ( Site 2902)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82-2-3410-1767
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Severance Hospital, Yonsei University Health System ( Site 2903)
-
Contacto:
- Study Coordinator
- Número de teléfono: +82-2-2228-8138
-
-
-
-
Capital Region
-
Herlev, Capital Region, Dinamarca, 2730
- Reclutamiento
- Herlev Hospital ( Site 1002)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00 45 38689191
-
-
Central Jutland
-
Aarhus, Central Jutland, Dinamarca, 8200
- Reclutamiento
- Aarhus Universitetshospital, Skejby ( Site 1001)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4591167472
-
-
Region Syddanmark
-
Odense, Region Syddanmark, Dinamarca, 5000
- Reclutamiento
- Odense Universitets Hospital ( Site 1000)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4566113333
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitari Vall d Hebron ( Site 2303)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34934894350
-
Las Palmas, España, 35016
- Reclutamiento
- Hospital Insular de Gran Canaria ( Site 2308)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34928441738
-
Madrid, España, 28041
- Reclutamiento
- Hospital Universitario 12 de Octubre ( Site 2300)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34913908339
-
Valencia, España, 46009
- Reclutamiento
- Fundación Instituto Valenciano de Oncología ( Site 2307)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34961114229
-
-
Andalusia
-
Seville, Andalusia, España, 41013
- Reclutamiento
- Hospital Universitario Virgen del Rocio ( Site 2306)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34955013068
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, España, 08908
- Reclutamiento
- Institut Català d'Oncologia - L'Hospitalet ( Site 2305)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34932607744
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, España, 28007
- Reclutamiento
- HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301)
-
Contacto:
- Study Coordinator
- Número de teléfono: +34914269393
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope Comprehensive Cancer Center ( Site 0129)
-
Contacto:
- Study Coordinator
- Número de teléfono: 877-817-9982
-
Irvine, California, Estados Unidos, 92618
- Reclutamiento
- City of Hope Lennar Foundation Cancer Center ( Site 0142)
-
Contacto:
- Study Coordinator
- Número de teléfono: see site 0129
-
-
Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Reclutamiento
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0102)
-
Contacto:
- Study Coordinator
- Número de teléfono: 770-281-5124
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Reclutamiento
- University of Louisville, James Graham Brown Cancer Center ( Site 0133)
-
Contacto:
- Study Coordinator
- Número de teléfono: 502-562-4673
-
Louisville, Kentucky, Estados Unidos, 40207
- Reclutamiento
- Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0104)
-
Contacto:
- Study Coordinator
- Número de teléfono: 502-899-3366
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Beth Israel Deaconess Medical Center ( Site 0139)
-
Contacto:
- Study Coordinator
- Número de teléfono: 617-667-7000
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana Farber Cancer Institute ( Site 0135)
-
Contacto:
- Study Coordinator
- Número de teléfono: 617-632-3000
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Reclutamiento
- The Cancer and Hematology Centers ( Site 0123)
-
Contacto:
- Study Coordinator
- Número de teléfono: 616-954-9800
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University School of Medicine ( Site 0114)
-
Contacto:
- Study Coordinator
- Número de teléfono: 314-362-7355
-
-
New Jersey
-
Hackensack, New Jersey, Estados Unidos, 07601
- Reclutamiento
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 0108)
-
Contacto:
- Study Coordinator
- Número de teléfono: 551-996-5900
-
Morristown, New Jersey, Estados Unidos, 07960
- Reclutamiento
- Atlantic Health System Morristown Medical Center ( Site 0109)
-
Contacto:
- Study Coordinator
- Número de teléfono: 973-971-7960
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Memorial Sloan Kettering Cancer Center ( Site 0126)
-
Contacto:
- Study Coordinator
- Número de teléfono: 347-798-9213
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Reclutamiento
- The West Clinic, P.C. ( Site 0115)
-
Contacto:
- Study Coordinator
- Número de teléfono: 901-683-0055
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- UT Southwestern Medical Center ( Site 0119)
-
Contacto:
- Study Coordinator
- Número de teléfono: 214-648-3111
-
-
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Francia, 06189
- Reclutamiento
- Centre Antoine Lacassagne ( Site 1209)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33492031538
-
-
Bouches-du-Rhone
-
Marseille, Bouches-du-Rhone, Francia, 13003
- Reclutamiento
- Hopital Europeen Marseille ( Site 1216)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33413427427
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, Francia, 31059
- Reclutamiento
- LBM ONCOPOLE CLAUDIUS REGAUD ( Site 1215)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33531155050
-
-
Maine-et-Loire
-
Angers, Maine-et-Loire, Francia, 49933
- Reclutamiento
- CHU Angers ( Site 1204)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33241354694
-
-
Pays de la Loire Region
-
Le Mans, Pays de la Loire Region, Francia, 72000
- Reclutamiento
- Clinique Victor Hugo Le Mans-Oncology-Radiotherapy ( Site 1203)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33 243297908
-
Saint Priest En Jarez, Pays de la Loire Region, Francia, 42271
- Reclutamiento
- CHU de Saint-Etienne ( Site 1202)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33477917082
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Francia, 94800
- Reclutamiento
- Gustave Roussy ( Site 1214)
-
Contacto:
- Study Coordinator
- Número de teléfono: +33142114211
-
-
-
-
Attica
-
Athens, Attica, Grecia, 185 47
- Reclutamiento
- Metropolitan Hospital ( Site 1402)
-
Contacto:
- Study Coordinator
- Número de teléfono: +302104809667
-
Athens, Attica, Grecia, 124 62
- Reclutamiento
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 1401)
-
Contacto:
- Study Coordinator
- Número de teléfono: +302105832549
-
Athens, Attica, Grecia, 115 28
- Reclutamiento
- Alexandra General Hospital of Athens ( Site 1400)
-
Contacto:
- Study Coordinator
- Número de teléfono: +302132162543
-
-
-
-
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus ( Site 1600)
-
Contacto:
- Study Coordinator
- Número de teléfono: +97247772688
-
Kfar Saba, Israel, 4428164
- Reclutamiento
- Meir Medical Center. ( Site 1603)
-
Contacto:
- Study Coordinator
- Número de teléfono: +97297472555
-
Petah Tikva, Israel, 4941492
- Reclutamiento
- Rabin Medical Center ( Site 1602)
-
Contacto:
- Study Coordinator
- Número de teléfono: 97239378074
-
Ramat Gan, Israel, 5265601
- Reclutamiento
- Sheba Medical Center ( Site 1601)
-
Contacto:
- Study Coordinator
- Número de teléfono: 97235303030
-
-
-
-
-
Bari, Italia, 70124
- Reclutamiento
- Azienda Ospedaliera Policlinico di Bari ( Site 1802)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00390805593767
-
Bologna, Italia, 40138
- Reclutamiento
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 1803)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390512142204
-
Milan, Italia, 20133
- Reclutamiento
- Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1800)
-
Contacto:
- Study Coordinator
- Número de teléfono: 02 2390 3028
-
Perugia, Italia, 06132
- Reclutamiento
- AO Santa Maria della Misericordia ( Site 1805)
-
Contacto:
- Study Coordinator
- Número de teléfono: +39 0755784188
-
Roma, Italia, 00168
- Reclutamiento
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1801)
-
Contacto:
- Study Coordinator
- Número de teléfono: 00390630155202
-
Roma, Italia, 00144
- Reclutamiento
- Istituto Nazionale Tumori Regina Elena ( Site 1804)
-
Contacto:
- Study Coordinator
- Número de teléfono: +39 0652666919
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italia, 47014
- Reclutamiento
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 1809)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390543739100
-
-
Milano
-
Rozzano, Milano, Italia, 20089
- Reclutamiento
- Istituto Clinico Humanitas ( Site 1808)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0282244061
-
-
Treviso
-
Castelfranco Veneto, Treviso, Italia, 31033
- Reclutamiento
- Istituto Oncologico Veneto IRCCS ( Site 1806)
-
Contacto:
- Study Coordinator
- Número de teléfono: +39 0423732336
-
-
Tuscany
-
Florence, Tuscany, Italia, 50134
- Reclutamiento
- Azienda Ospedaliera Universitaria Careggi ( Site 1807)
-
Contacto:
- Study Coordinator
- Número de teléfono: +390557949648
-
-
-
-
Limburg
-
Maastricht, Limburg, Países Bajos, 6229 HX
- Reclutamiento
- Maastricht UMC+ ( Site 1901)
-
Contacto:
- Study Coordinator
- Número de teléfono: +31433877025
-
-
North Holland
-
Amsterdam, North Holland, Países Bajos, 1066 CX
- Reclutamiento
- Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900)
-
Contacto:
- Study Coordinator
- Número de teléfono: +3120 512 9111
-
-
South Holland
-
Schiedam, South Holland, Países Bajos, 3118 JH
- Reclutamiento
- Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1903)
-
Contacto:
- Study Coordinator
- Número de teléfono: +31108931441
-
The Hague, South Holland, Países Bajos, 2545 AA
- Reclutamiento
- Haga Ziekenhuis locatie Leyweg ( Site 1906)
-
Contacto:
- Study Coordinator
- Número de teléfono: +3170 210 2143
-
-
-
-
Greater Poland Voivodeship
-
Skórzewo, Greater Poland Voivodeship, Polonia, 60-185
- Reclutamiento
- AIDPORT Sp. z o.o. ( Site 2118)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48570783100
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polonia, 30-727
- Reclutamiento
- Pratia MCM Krakow ( Site 2115)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48122958160
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polonia, 08-110
- Reclutamiento
- Mazowiecki Szpital Wojewódzki im. Sw. Jana Pawla II w Siedlcach Sp. z o.o. ( Site 2102)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48256403300
-
Warsaw, Masovian Voivodeship, Polonia, 02-172
- Reclutamiento
- MTZ Clinical Research Powered by Pratia ( Site 2107)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48225725959
-
Warsaw, Masovian Voivodeship, Polonia, 02-781
- Reclutamiento
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 2100)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48225462331
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Polonia, 44-102
- Reclutamiento
- Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2106)
-
Contacto:
- Study Coordinator
- Número de teléfono: +48322788237
-
-
-
-
-
Birmingham, Reino Unido, B15 2GW
- Reclutamiento
- University Hospitals Birmingham NHS Foundation Trust ( Site 2610)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4407789651543
-
Cardiff, Reino Unido, CF14 2TL
- Reclutamiento
- Velindre Cancer Centre ( Site 2612)
-
Contacto:
- Study Coordinator
- Número de teléfono: +442920615888
-
Southampton, Reino Unido, SO16 6YD
- Reclutamiento
- University Hospital of Southampton ( Site 2606)
-
Contacto:
- Study Coordinator
- Número de teléfono: 023 8077 7222
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 0QQ
- Reclutamiento
- Addenbrookes Hospital ( Site 2605)
-
Contacto:
- Study Coordinator
- Número de teléfono: +441223805000
-
-
Edinburgh, City of
-
Edinburgh, Edinburgh, City of, Reino Unido, EH4 2XU
- Reclutamiento
- Western General Hospital ( Site 2608)
-
Contacto:
- Study Coordinator
- Número de teléfono: +441315371398
-
-
Glasgow City
-
Glasgow, Glasgow City, Reino Unido, G12 0YN
- Reclutamiento
- The Beatson West of Scotland Cancer Centre ( Site 2602)
-
Contacto:
- Study Coordinator
- Número de teléfono: +441413019916
-
-
Leicestershire
-
Leicester, Leicestershire, Reino Unido, LE1 5WW
- Reclutamiento
- Leicester Royal Infirmary ( Site 2604)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0300 303 1573
-
-
London, City of
-
Northwood, London, City of, Reino Unido, HA6 2RN
- Reclutamiento
- Mount Vernon Hospital ( Site 2607)
-
Contacto:
- Study Coordinator
- Número de teléfono: +4401923826111
-
-
Manchester
-
Withington, Manchester, Reino Unido, M20 4BX
- Reclutamiento
- The Christie Hospital NHS Foundation Trust ( Site 2601)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0161 918 2546
-
-
-
-
-
Adana, Turquía (Türkiye), 01140
- Reclutamiento
- Adana Medical Park Seyhan Hastanesi ( Site 2505)
-
Contacto:
- Study Coordinator
- Número de teléfono: +905372688986
-
Ankara, Turquía (Türkiye), 06620
- Reclutamiento
- Ankara University Health Practice and Research Hospitals ( Site 2506)
-
Contacto:
- Study Coordinator
- Número de teléfono: +90 312 595 71 12
-
Edirne, Turquía (Türkiye), 22030
- Reclutamiento
- Trakya University Medical Faculty Hospital ( Site 2502)
-
Contacto:
- Study Coordinator
- Número de teléfono: +9005378528123
-
Istanbul, Turquía (Türkiye), 34010
- Reclutamiento
- Koc Universitesi Hastanesi ( Site 2501)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0090 850 250 8 250
-
Izmir, Turquía (Türkiye), 35080
- Reclutamiento
- Ege Universitesi Hastanesi ( Site 2503)
-
Contacto:
- Study Coordinator
- Número de teléfono: 0 232 343 43 43
-
-
Ankara
-
Sıhhiye, Ankara, Turquía (Türkiye), 06230
- Reclutamiento
- Hacettepe Universite Hastaneleri ( Site 2500)
-
Contacto:
- Study Coordinator
- Número de teléfono: +905439340493
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a histologically confirmed diagnosis of unresectable, advanced renal cell carcinoma (RCC) with clear cell component (with or without sarcomatoid features) ie, Stage IV RCC per American Joint Committee on Cancer (8th Edition)
- Has measurable disease per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)
- Has received no more than 3 prior systemic regimens for RCC, including only 1 prior anti-Programmed Cell Death-1/Programmed Cell Death 1 Ligand 1 therapy
Exclusion Criteria:
For exclusion criteria: The main exclusion criteria include but are not limited to the following:
- Has any of the following: a pulse oximeter reading <92% at rest, requires intermittent supplemental oxygen, or required chronic supplemental oxygen
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
- Has deep vein thrombosis within 3 months before randomization unless stable, asymptomatic, and treated with therapeutic anticoagulation for at least 4 weeks before randomization
- Has a left ventricular ejection fraction ≤50% or below the institutional (or local laboratory) normal range as determined by multigated acquisition or echocardiogram
- Has had major surgery within 8 weeks before randomization
- Has current pneumonitis/interstitial lung disease
- Has a history of human immunodeficiency virus infection
- Has Hepatitis B or Hepatitis C virus infection
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has a history of solid organ transplant
- Has not adequately recovered from major surgery or has ongoing surgical complications
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Triple
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Belzutifan + Zanzalintinib
Participants will receive 120 mg belzutifan orally and 60 mg zanzalintinib once daily for approximately 24 months. |
Tablet for oral administration.
Otros nombres:
Tablet for oral administration.
Otros nombres:
|
|
Comparador activo: Belzutifan + Placebo
Participants will receive 120 mg belzutifan orally and zanzalintinib-matching placebo once daily for approximately 24 months. |
Tablet for oral administration.
Otros nombres:
Zanzalintinib-matching placebo tablet for oral administration. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free Survival (PFS)
Periodo de tiempo: Up to approximately 30 months
|
PFS is defined as the time from randomization to the first documented disease progression per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. |
Up to approximately 30 months
|
|
Overall Survival (OS)
Periodo de tiempo: Up to approximately 50 months
|
OS is defined as the time from randomization to death due to any cause. |
Up to approximately 50 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR)
Periodo de tiempo: Up to approximately 30 months
|
ORR is defined as the percentage of participants who have achieved confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 as assessed by BICR. |
Up to approximately 30 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to approximately 30 months
|
DOR is defined as the interval from the first documented evidence of a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 until Progressive Disease (PD) or death due to any cause, whichever occurs first, in participants demonstrating a best confirmed response of CR or PR. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. |
Up to approximately 30 months
|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
Periodo de tiempo: Up to approximately 25 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported. |
Up to approximately 25 months
|
|
Number of Participants who Discontinue Study Treatment Due to an AE
Periodo de tiempo: Up to approximately 24 months
|
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Periodo de tiempo: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score
Periodo de tiempo: Baseline and up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score will be presented. |
Baseline and up to approximately 25 months
|
|
Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score
Periodo de tiempo: Baseline and up to approximately 25 months
|
The EORTC QLQ-C30 is a cancer specific health-related quality of life questionnaire. The role functioning score is based on participant responses to questions scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score was computed by averaging the raw scores of Items 6 and 7 and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. Higher scores indicate better role functioning. The change from baseline in EORTC QLQ-C30 Role Functioning (Items 6 and 7) combined score will be reported. |
Baseline and up to approximately 25 months
|
|
Change From Baseline in Disease Symptoms Using the Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease-related Symptoms (FKSI-DRS) (Items 1-9) Score
Periodo de tiempo: Baseline and up to approximately 25 months
|
The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. |
Baseline and up to approximately 25 months
|
|
Time to Deterioration (TTD) in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score
Periodo de tiempo: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") were scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) was computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1-5) Score
Periodo de tiempo: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 was computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in EORTC QLQ-C30 Role Functioning (Items 6 and 7) Score
Periodo de tiempo: Up to approximately 25 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to questions about their role functioning (Items 6 and 7) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of Items 6 and 7 was computed by averaging the raw scores of the items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD was defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in role functioning (Items 6 and 7). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
|
TTD in Disease Symptoms Using the FKSI-DRS (Items 1-9) Score
Periodo de tiempo: Up to approximately 25 months
|
TTD is defined as time from the first dose of study treatment to the date of deterioration of FKSI-DRS score. The FKSI-DRS index consists of a 9-item questionnaire that assesses the extent of participant symptoms from kidney cancer. Each item is scored on a 5-point scale (0=not at all to 4=very much). FKSI-DRS total score ranged from 0 (most severe symptoms) to 36 (no symptoms) with a higher score indicating a better outcome. Deterioration is defined as a 3-point decrease (i.e. lower score) in symptom score and the time to true deterioration is the time to first onset of 3 or more decreases from baseline with confirmation under right-censoring rule (the last observation). A longer TTD indicates a better outcome. |
Up to approximately 25 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Medical Director, Merck Sharp & Dohme LLC
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades urogenitales masculinas
- Enfermedades Renales
- Enfermedades urológicas
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Adenocarcinoma
- Neoplasias Urológicas
- Carcinoma
- Neoplasias Renales
- Carcinoma De Célula Renal
- belzutifan
Otros números de identificación del estudio
- 6482-034
- U1111-1311-4692 (Identificador de registro: UTN)
- 2024-516993-31-00 (Identificador de registro: EU CT)
- LITESPARK-034 (Otro identificador: MSD)
- MK-6482-034 (Otro identificador: MSD)
- LS-034 (Otro identificador: MSD)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .